Back to GetFilings.com



Table of Contents

 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

_____________________

         
(Mark One)        
þ   Quarterly Report Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
   

For the quarterly period ended March 27, 2005

OR

         
o   Transition Report Pursuant to Section 13 or 15(d) of the    
  Securities Exchange Act of 1934    

Commission File No. 001-31353

EMULEX CORPORATION

(Exact name of registrant as specified in its charter)
     
Delaware   51-0300558
(State or other jurisdiction   (I.R.S Employer
of incorporation or organization)   Identification No.)
     
3333 Susan Street    
Costa Mesa, California   92626
(Address of principal executive offices)   (Zip Code)

(714) 662-5600
(Registrant’s telephone number, including area code)


Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes þ      No o

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).  Yes þ      No o

As of April 29, 2005 the registrant had 83,106,596 shares of common stock outstanding.

 
 

 


EMULEX CORPORATION AND SUBSIDIARIES

INDEX

             
        PAGE
Part I.   FINANCIAL INFORMATION        
  Financial Statements (Unaudited)        
 
 
Condensed Consolidated Balance Sheets
March 27, 2005 and June 27, 2004
    2  
 
Condensed Consolidated Statements of Income
Three and nine months ended March 27, 2005 and March 28, 2004
    3  
 
Condensed Consolidated Statements of Cash Flows
Nine months ended March 27, 2005 and March 28, 2004
    4  
 
Notes to Condensed Consolidated Financial Statements
    5  
  Management’s Discussion and Analysis of
Financial Condition and Results of Operations
    13  
  Quantitative and Qualitative Disclosures about Market Risk     36  
  Controls and Procedures     36  
Part II.   OTHER INFORMATION        
  Legal Proceedings     37  
  Unregistered Sales of Equity Securities and Use of Proceeds     38  
  Exhibits     39  
Signatures     41  
 EXHIBIT 31.A
 EXHIBIT 31.B
 EXHIBIT 32

1


Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

EMULEX CORPORATION AND SUBSIDIARIES

Condensed Consolidated Balance Sheets
(in thousands, except share data)
(unaudited)
                 
    March 27,     June 27,  
    2005   2004  
Assets
               
 
               
Current assets:
               
Cash and cash equivalents
  $ 154,886     $ 192,137  
Restricted cash
          23  
Investments
    343,235       220,114  
Accounts and other receivables, net
    54,167       61,720  
Litigation settlements receivable
          5,101  
Inventories, net
    26,842       31,835  
Prepaid expenses
    4,645       3,572  
Deferred income taxes
    21,449       26,824  
     
Total current assets
    605,224       541,326  
 
               
Property and equipment, net
    63,598       64,570  
Investments
    115,727       243,125  
Intangibles, net
    102,609       122,667  
Other assets
    837       1,293  
     
 
  $ 887,995     $ 972,981  
     
 
               
Liabilities and Stockholders’ Equity
               
 
               
Current liabilities:
               
Accounts payable
  $ 26,985     $ 21,747  
Accrued liabilities
    24,617       22,839  
Income taxes payable
    21,753       9,910  
     
Total current liabilities
    73,355       54,496  
 
               
Convertible subordinated notes
    359,771       524,845  
Deferred income taxes and other
    6,651       486  
     
Total liabilities
    439,777       579,827  
     
 
               
Commitments and contingencies (notes 7 and 8)
               
 
               
Stockholders’ equity:
               
Preferred stock, $0.01 par value; 1,000,000 shares authorized
(150,000 shares designated as Series A Junior Participating
Preferred Stock); none issued and outstanding
           
Common stock, $0.10 par value; 240,000,000 shares authorized;
82,911,045 and 82,413,845 shares issued and outstanding at
March 27, 2005, and June 27, 2004, respectively
    8,291       8,241  
Additional paid-in capital
    941,201       936,123  
Deferred compensation
    (4,106 )     (7,754 )
Accumulated deficit
    (497,168 )     (543,456 )
     
Total stockholders’ equity
    448,218       393,154  
     
 
  $ 887,995     $ 972,981  
     

See accompanying notes to the condensed consolidated financial statements.

2


Table of Contents

EMULEX CORPORATION AND SUBSIDIARIES

Condensed Consolidated Statements of Income
(in thousands, except share data)
(unaudited)
                                 
    Three Months Ended   Nine Months Ended  
    March 27,     March 28,     March 27,     March 28,  
    2005   2004   2005   2004  
Net revenues
  $ 102,580     $ 99,038     $ 267,476     $ 277,984  
Cost of sales
    37,446       36,374       100,238       99,507  
     
Gross profit
    65,134       62,664       167,238       178,477  
     
 
                               
Operating expenses:
                               
Engineering and development
    21,042       19,046       60,985       53,701  
Selling and marketing
    8,004       8,366       23,015       19,818  
General and administrative
    4,223       6,014       7,381       15,259  
Amortization of intangibles
    6,547       6,795       19,642       12,546  
Impairment of goodwill
                1,793        
In-process research and development
                      11,400  
     
Total operating expenses
    39,816       40,221       112,816       112,724  
     
 
                               
Operating income
    25,318       22,443       54,422       65,753  
     
 
                               
Nonoperating income:
                               
Interest income
    3,341       2,224       9,242       6,700  
Interest expense
    (1,016 )     (1,525 )     (3,419 )     (3,285 )
Gain (loss) on repurchase of
convertible subordinated notes
    (279 )     (231 )     12,811       2,670  
Other income (expense), net
    (24 )     (23 )     48       141  
     
Total nonoperating income
    2,022       445       18,682       6,226  
     
 
                               
Income before income taxes
    27,340       22,888       73,104       71,979  
 
                               
Income tax provision
    9,552       8,560       26,816       31,448  
     
 
                               
Net income
  $ 17,788     $ 14,328     $ 46,288     $ 40,531  
     
 
                               
Net income per share:
                               
Basic
  $ 0.21     $ 0.18     $ 0.56     $ 0.49  
     
Diluted
  $ 0.20     $ 0.16     $ 0.52     $ 0.46  
     
Number of shares used in per share
computations:
                               
Basic
    82,963       81,872       82,710       82,928  
     
Diluted
    93,415       96,571       93,467       91,481  
     

See accompanying notes to the condensed consolidated financial statements.

3


Table of Contents

EMULEX CORPORATION AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows
(in thousands)
(unaudited)
                 
    Nine Months Ended  
    March 27,     March 28,  
    2005   2004  
Cash flows from operating activities:
               
 
               
Net income
  $ 46,288     $ 40,531  
Adjustments to reconcile net income to net cash
provided by operating activities:
               
Depreciation and amortization of property and equipment
    10,723       9,254  
Amortization of discount on 0.25% convertible subordinated notes
    2,262       1,052  
Gain on repurchase of convertible subordinated notes
    (12,811 )     (2,670 )
Insurance recovery on shareholder litigation settlements
    (4,649 )      
Stock-based compensation
    3,305       5,265  
Amortization of other intangibles
    19,642       12,546  
Impairment of goodwill
    1,793        
In-process research and development
          11,400  
Deferred income taxes
    9,753       7,932  
Tax benefit from exercise of stock options
    1,619       5,597  
Other
    22       172  
Changes in assets and liabilities:
               
Accounts and other receivables
    7,553       (12,026 )
Inventories
    4,993       (18,285 )
Prepaid expenses and other assets
    (974 )     2,466  
Accounts payable and accrued liabilities
    7,806       7,405  
Payment of litigation settlements, net of reimbursement
    9,052       (31,506 )
Income taxes payable
    11,843       11,086  
     
Net cash provided by operating activities
    118,220       50,219  
     
Cash flows from investing activities:
               
Net proceeds from sale of property and equipment
    42       53  
Additions to property and equipment
    (9,815 )     (42,743 )
Decrease in restricted cash related to the construction escrow account
    23       9,096  
Payments for Vixel Corporation, net of cash acquired
          (294,096 )
Payments for the technology assets of Trebia Networks, Inc.
          (2,094 )
Purchases of investments
    (560,490 )     (280,149 )
Maturities of investments
    564,767       317,479  
     
Net cash used in investing activities
    (5,473 )     (292,454 )
     
Cash flows from financing activities:
               
Repayment of short term indebtedness, notes payable and capital leases
          (175,290 )
Proceeds from short term indebtedness
          174,000  
Proceeds from issuance of common stock under stock option and
employee stock purchase plans
    4,268       10,348  
Repurchase of common stock
          (40,500 )
Net proceeds from issuance of 0.25% convertible subordinated notes
          505,179  
Repurchase of convertible subordinated notes
    (154,266 )     (185,609 )
     
Net cash provided by (used in) financing activities
    (149,998 )     288,128  
     
Net increase (decrease) in cash and cash equivalents
    (37,251 )     45,893  
Cash and cash equivalents at beginning of period
    192,137       136,971  
     
Cash and cash equivalents at end of period
  $ 154,886     $ 182,864  
     
Supplemental disclosures:
               
Noncash investing and financing activities:
               
Fair value of assets acquired
  $     $ 20,936  
Fair value of liabilities assumed
          13,449  
Stock options assumed for acquired business
          47,538  
Cash paid during the period for:
               
Interest
  $ 761     $ 2,226  
Income taxes
    3,836       6,888  

See accompanying notes to the condensed consolidated financial statements.

4


Table of Contents

EMULEX CORPORATION AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

1.   Summary of Significant Accounting Policies and Basis of Presentation
 
    In the opinion of the Company, the accompanying unaudited condensed consolidated financial statements contain all adjustments (which are normal recurring accruals) necessary to present fairly its financial position as of March 27, 2005, and June 27, 2004, and its condensed consolidated statements of income for the three and nine months ended March 27, 2005, and March 28, 2004 and its condensed consolidated statements of cash flows for the nine months then ended. Interim results for the nine months ended March 27, 2005, are not necessarily indicative of the results that may be expected for the year ending July 3, 2005. The interim financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the fiscal year ended June 27, 2004.
 
    New Accounting Standards
 
    Emerging Issues Task Force Issue 04-08, “The Effect of Contingently Convertible Debt on Diluted Earnings per Share,” (“EITF 04-08”) became effective for fiscal periods ending after December 15, 2004. EITF 04-08 requires the inclusion of shares related to certain contingently convertible debt instruments for computing diluted earnings per share using the if-converted method, even when a market price contingency has not been met. The effect of EITF 04-08 has increased our weighted average shares outstanding by approximately 8.4 million (related to the Company’s outstanding 0.25 percent contingent convertible subordinated notes of $364.5 million issued in December 2003 and January 2004) in calculating the Company’s diluted earnings per share calculation for the quarter ended March 27, 2005. Prior periods earnings per share amounts presented for comparative purposes have been restated to conform to this method.
 
    In November 2004, the Financial Accounting Standards Board (“FASB”) issued Statement of Financial Accounting Standard (“SFAS”) No. 151 “Inventory Costs, an amendment of ARB No. 43, Chapter 4.” The amendments made by SFAS No. 151 clarify that abnormal amounts of idle facility expense, freight, handling costs, and wasted materials (spoilage) should be recognized as current-period charges and require the allocation of fixed production overheads to inventory based on the normal capacity of the production facilities. The guidance is effective for inventory costs incurred during fiscal years beginning after June 15, 2005. The Company does not believe SFAS No. 151 will have a significant impact on the Company’s consolidated results of operations or financial position.
 
    In December 2004, the FASB issued SFAS No. 153, “Exchanges of Nonmonetary Assets, an amendment of APB Opinion No. 29, Accounting for Nonmonetary Transactions”. SFAS No. 153 states that exchanges of nonmonetary assets should be measured based on the fair value of the assets exchanged. Further, SFAS No. 153 eliminates the narrow exception for nonmonetary exchanges of similar productive assets and replaces it with a broader exception for exchanges of nonmonetary assets that do not have commercial substance. SFAS No. 153 is effective for nonmonetary asset exchanges occurring in fiscal periods beginning after June 15, 2005. The provisions of SFAS No. 153 shall be applied prospectively. The Company does not believe the adoption of SFAS No. 153 will have a significant impact on the Company’s consolidated results of operations or financial position.
 
    In November 2003, the EITF reached an interim consensus on EITF 03-01, “The Meaning of Other-Than-Temporary Impairment and its Application to Certain Investments,” to require additional disclosure requirements for securities classified as available-for-sale or held-to-maturity for fiscal years ending after December 15, 2003. In March 2004, the EITF reached a final consensus on this Issue, to provide additional guidance, which companies must follow in determining whether investment securities have an impairment, which should be considered other-than-temporary. The effective date of this consensus has been delayed pending further FASB action. EITF 03-01 is not expected to have a significant impact on the carrying value of the Company’s investments.
 
    In December 2004, the FASB issued two FASB Staff Positions (“FSPs”) that provide accounting guidance on how companies should account for the effects of the American Jobs Creations Act of 2004 (“the Act”) that was signed into law on October 22, 2004. The Act could affect how companies report their deferred income tax balances. The FSPs are FSP 109-1(“FSP 109-1”); the second is FSP 109-2 (“FSP 109-2”). In FSP 109-1, the FASB concludes that the tax relief (special tax deduction for domestic manufacturing) from the Act should be

5


Table of Contents

EMULEX CORPORATION AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

    accounted for as a “special deduction” instead of a tax rate reduction. FSP 109-2 gives a company additional time to evaluate the effects of the Act on any plan for Income Taxes. However, companies must provide certain disclosures if they choose to utilize the additional time granted by the FASB. The Company is evaluating the impact, if any, these FSPs may have on its results of operations, financial condition or cash flows.
 
    In December 2004, the FASB issued SFAS No. 123 (revised 2004), “Share-Based Payment”. SFAS No. 123R requires that the compensation cost relating to share-based payment transactions be recognized in financial statements. That cost will be measured based on the fair value of the equity or liability instruments issued. SFAS No. 123R covers a wide range of share-based compensation arrangements including share options, restricted share plans, performance-based awards, share appreciation rights, and employee share purchase plans. SFAS No. 123R replaces SFAS No. 123, “Accounting for Stock-Based Compensation”, and supersedes Accounting Principles Board (“APB”) Opinion No. 25, “Accounting for Stock Issued to Employees.” SFAS No. 123R is effective as of the first annual reporting period that begins after June 15, 2005; however, early adoption is permitted. The Company is currently evaluating its alternatives, which will likely include early adoption during the three months ending July 3, 2005. The adoption of SFAS No. 123R will have a significant impact on the Company’s results of operations, as demonstrated by the SFAS No. 123 pro-forma disclosures below.
 
    Stock-Based Compensation
 
    The Company currently accounts for its stock-based awards to employees using the intrinsic value method under APB 25 and related interpretations. Stock-based awards to non-employees, if any, are recorded using the fair value method. Had the Company determined compensation cost based on the fair value at the grant date for all its stock options under SFAS No. 123, the Company’s net income would have been the pro forma amounts indicated below (in thousands, except per share data):

                                 
    Three Months Ended   Nine Months Ended  
    March 27,     March 28,     March 27,     March 28,  
    2005   2004   2005   2004  
Net income as reported
  $ 17,788     $ 14,328     $ 46,288     $ 40,531  
Add: total employee stock-based compensation expense included in net income as reported, net of related tax effects
    622       1,596       2,301       3,924  
Deduct: Total employee stock-based compensation expense determined under fair value method for all awards, net of related tax effects
    (5,419 )     (2,925 )     (18,898 )     (22,507 )
     
Pro forma net income
  $ 12,991     $ 12,999     $ 26,691     $ 21,948  
     
Pro forma net income per share
                               
Basic — as reported
  $ 0.21     $ 0.18     $ 0.56     $ 0.49  
     
Basic — pro forma
  $ 0.16     $ 0.16     $ 0.36     $ 0.26  
     
Diluted — as reported
  $ 0.20     $ 0.16     $ 0.52     $ 0.46  
     
Diluted — pro forma
  $ 0.15     $ 0.14     $ 0.34     $ 0.26  
     

6


Table of Contents

EMULEX CORPORATION AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

    The fair value of each option granted during the three and nine months ended March 27, 2005, and March 28, 2004, was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions:

                                 
    Three Months Ended   Nine Months Ended  
    March 27,     March 28,     March 27,     March 28,  
    2005   2004   2005   2004  
Risk-free interest rate
    4.0%       2.1%           2.0% - 4.0%           1.0% - 2.5%  
Stock volatility
    50.0%       106.1%       50.0% - 84.0%       41.0% - 117.7%  
Dividend yield
    0.0%       0.0%       0.0%       0.0%  
Average expected lives (years)
    2.9       3.4       0.5 - 2.9       0.5 - 3.4  
Weighted-average fair value
per option granted
    $6.08       $17.98       $3.49 - $6.08       $4.92 - $17.98  

    The Black-Scholes model, and other currently accepted option valuation models, were developed to estimate the fair value of freely-tradable, fully-transferable options without vesting restrictions, which significantly differ from the Company’s stock option plans. These models also require highly subjective assumptions, including future stock price volatility and expected time until exercise, which greatly affect the calculated fair value on the grant date.
 
2.   Business Combination
 
    On November 13, 2003, the Company completed the cash tender offer to acquire all outstanding shares of Vixel Corporation. On November 17, 2003, the Company completed its acquisition of Vixel. The Company acquired Vixel to expand its Fibre Channel product line and paid $298.4 million in cash for all outstanding common stock, preferred stock and warrants of Vixel Corporation. The Company also incurred acquisition-related expenses of $6.7 million in cash. In addition, the Company issued 2.2 million stock options with a fair value of approximately $47.5 million and kept the original vesting periods for the options in exchange for the outstanding Vixel options for a total acquisition value of $352.7 million. The Company calculated the fair value of the 2.2 million stock options issued at the date of acquisition using the Black-Scholes option-pricing model.
 
    The acquisition has been included in the condensed consolidated balance sheets of the Company and the operating results of Vixel have been included in the condensed consolidated statements of operations of the Company since the date that the Company gained effective control of Vixel, November 13, 2003. Operations of Vixel, since the acquisition, have been included within the Company’s one operating segment, networking products.
 
    In connection with the preparation of Vixel Corporation’s tax return in the first quarter of fiscal 2005, the Company revised estimates and discovered errors related to the deferred tax assets of Vixel Corporation (acquired in November 2003). As a result, the Company recorded a $1.8 million impairment of goodwill in the three months ended September 26, 2004. Had these items been recorded in fiscal 2004, the Company’s net loss would have been $1.8 million higher, or $534.1 million, instead of $532.3 million. The Company does not believe that this $1.8 million impairment of goodwill is material to fiscal 2004 or will be material to fiscal 2005 operations or financial results. Excluding this adjustment, net income for the nine months ended March 27, 2005, would have been $48.1 million.
 
3.   Inventories
 
    Inventories, net, are summarized as follows:

                 
    March 27,     June 27,  
    2005   2004  
    (in thousands)  
Raw materials
  $ 13,857     $ 19,181  
Finished goods
    12,985       12,654  
     
 
  $ 26,842     $ 31,835  
     

7


Table of Contents

EMULEX CORPORATION AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

4.   Intangibles
 
    Intangibles, net, are as follows:

                 
    March 27,     June 27,  
    2005   2004  
    (in thousands)  
Intangible assets subject to amortization:
               
Core technology and patents
  $ 98,884     $ 99,094  
Accumulated amortization, core technology and patents
    (35,613 )     (24,774 )
Developed technology
    9,365       9,400  
Accumulated amortization, developed technology
    (3,234 )     (1,472 )
Customer relationships
    38,058       38,200  
Accumulated amortization, customer relationships
    (10,516 )     (4,786 )
Tradename
    4,981       5,000  
Accumulated amortization, tradename
    (983 )     (448 )
Covenants not-to-compete
    3,089       3,100  
Accumulated amortization, covenants not-to-compete
    (1,422 )     (647 )
     
Intangible assets subject to amortization
  $ 102,609     $ 122,667  
     

    The recorded value of the specifically-identified intangible assets associated with the acquisition of Vixel were reduced during the three months ended March 27, 2005, by $0.4 million related to tax benefits associated with stock option exercises.
 
    The intangible assets subject to amortization are being amortized on a straight-line basis over lives ranging from two to seven years. Aggregated amortization expense for these intangibles for the three and nine months ended March 27, 2005, was $6.5 million and $19.6 million, respectively. For the following five full fiscal years aggregated amortization expense is expected to be (in thousands):

         
2005
  $ 26,162  
2006
  $ 26,019  
2007
  $ 25,341  
2008
  $ 21,215  
2009
  $ 11,550  

5.   Other Assets
 
    Components of other assets are as follows:

                 
    March 27,     June 27,  
    2005   2004  
    (in thousands)  
Deferred debt issuance costs-
convertible subordinated notes, net
  $ 282     $ 833  
Long-term prepaid assets
    451       236  
Refundable deposits
    104       224  
     
 
  $ 837     $ 1,293  
     

6.   Accrued Liabilities
 
    Components of accrued liabilities are as follows:

                 
    March 27     June 27,  
    2005   2004  
    (in thousands)  
Payroll and related costs
  $ 8,324     $ 8,936  
Warranty reserves
    4,767       4,046  
Deferred revenue
    1,492       1,561  
Accrued advertising and promotions
    1,473       1,139  
Accrued property, sales, franchise and related taxes
    2,225       1,938  
Other
    6,336       5,219  
     
Intangible assets subject to amortization
  $ 24,617     $ 22,839  
     

8


Table of Contents

EMULEX CORPORATION AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

    Deferred revenue includes an accrual for estimated returns and allowances of $1.5 million at March 27, 2005 and June 27, 2004.
 
    The Company provides a warranty of between one and five years on its products. The Company records a provision for estimated warranty-related costs based on historical product returns and the Company’s expected future cost of fulfilling its warranty obligations.
 
    Changes to the warranty reserve for the three and nine months ended March 27, 2005, and March 28, 2004, were:

                                 
    Three Months Ended   Nine Months Ended